A new WHO classification of prostate tumors

Франк, Г. А.; Andreeva, Yu Yu; Moskvina, L V; Ефремов, Г. Д.; Самойлова, С. И.

doi:10.17116/patol201678432-42

Cited by 13 publications

(16 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All these confounding factors may have affected our results. For example, the most recent 2012 WHO classification of breast cancer distinguishes the ILC and its variants: classic, solid, alveolar, pleomorphic, tubulo-lobular, and mixed variant [1]. Lack of E-cadherin is observed in all histological ILC variants, except for tubulo-lobular variant (tubulo-lobular carcinoma, TLC).…”

Section: Discussionmentioning

confidence: 99%

“…Invasive lobular carcinoma (ILC) is the most common 'special' morphological subtype of breast cancer and presents with a distinctive clinical behavior compared with invasive ductal carcinoma (IDC) (no special type) [1,2]. Classical ILC is characterized by monotonous small, uniform, discohesive cells that infiltrate the stroma in a single-file pattern [2].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

Hu²,

Zhang

et al. 2019

Preprint

View full text Add to dashboard Cite

Background : The benefit of adjuvant chemotherapy in invasive lobular carcinoma (ILC) is still unclear. The objective of the current study was to elucidate the effectiveness of adjuvant chemotherapy in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, pT1b-c/N0-1/M0 ILC. Methods: Based on Surveillance, Epidemiology, and End-Results (SEER) database, we identified original 13996 HR-positive, HER2-negative, pT1b-c/N0-1/M0 ILC patients, who were then divided into adjuvant chemotherapy group and control group. End-points were overall survival (OS) and breast cancer-specific mortality (BCSM). Aiming to minimize the selection bias of baseline characteristics, Propensity Score Matching (PSM) method was used. Results : In a total of 13996 patients with HR-positive, HER2-negative, pT1b-c/N0-1/M0 ILC, 1800 patients (12.9%) were allocated into adjuvant chemotherapy group and 12196 (87.1%) into control group. Used PSM, the 1800 patients in adjuvant chemotherapy group matched to the 1800 patients in control group. By Kaplan-Meier survival analyses, we observed beneficial effect of adjuvant chemotherapy on OS in original samples ( P =0.001) but ineffectiveness in matched samples ( P =0.400), however, ineffective or even contrary results of adjuvant chemotherapy on BCSM both in original samples (P =0.001) and in matched samples ( P= 0.033). In both original and matched multivariate Cox models, we observed ineffectiveness of adjuvant chemotherapy on OS (hazard ratio (HR) for overall mortality = 1.243, 95% confidence interval (CI) [0.954-1.619]; P =0.108 and HR=1.227, 95%CI [0.870-1.731]; P =0.244, respectively), unexpectedly promoting effect of adjuvant chemotherapy on BCSM (HR=2.446, 95%CI [1.598-3.742]; P =0.001 and HR=1.791, 95%CI [1.056-3.037]; P = 0.031, respectively). Lymph node metastasis was detrimental to survival in original samples, but had unobvious effect in matched samples. Radiotherapy and standard surgery were beneficial to the survival of patients. Conclusion: Adjuvant chemotherapy could bring no survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 ILC, even contribute to BCSM.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

Hu²,

Zhang

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…2) дуктальная (протоковая) карцинома с вариантами крибриформным, папиллярным и солидным, встречается редко в 0,2 -0,4% наблюдений, расположена центрально вокруг простатической уретры, а в сочетании с ацинарной аденокарциномой располагается в периферической зоне -в 3,2%, при оценке Глисон соответствует 4-5 баллам (сумма Глисон 8-9 баллов), часто встречаются комедонекрозы (5 баллов, сумма Глисон 10 баллов) [5].…”

Section: правила вырезки препарата «предстательная железа» после рпэunclassified

Prostate pathological evaluation after radical prostatectomy

Лаптева

2019

Vestn. urol.

View full text Add to dashboard Cite

В статье приведены сведения о зональном строении предстательной железы (ПЖ), схема вырезки макропрепарата после радикальной простатэктомии (РПЭ), частота встречаемости рака предстательной железы (РПЖ) по зонам. Приведён обзор классификации ВОЗ (2016) опухолей предстательной железы, отмечены внесённые изменения, описаны подходы к диагностике вариантов рака, оценка по Глисон, определение градации, клинические прогностические группы риска РПЖ, оценки первичной опухоли согласно международной классификации РПЖ по системе TNM (AjCC 8-е изд.), которая была дополнена и пересмотрена в 2017 году, определены прогностические факторы для ацинарной карциномы и роль иммуногистохимической диагностики в материале ПЖ. В заключении указаны основные значимые параметры, которые должны быть отражены в протоколе прижизненного патологоанатомического исследования по материалу РПЭ. Ключевые слова: рак предстательной железы; аденокарцинома; радикальная простатэктомия; классификация ВОЗ; классификации рака предстательной железы по системе TNM (AjCC 8-е изд.); прогностические группы риска Раскрытие информации: Исследование не имело спонсорской поддержки. Автор заявляет об отсутствии конфликта интересов.

show abstract

“…and presents with a distinctive clinical behavior compared with invasive ductal carcinoma (IDC) (no special type) [1,2]. Classical ILC is characterized by monotonous small, uniform, discohesive cells that infiltrate the stroma in a single-file pattern [2].…”

Section: Introductionmentioning

confidence: 99%

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

Hu²,

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background : The benefit of adjuvant chemotherapy in invasive lobular carcinoma (ILC) is still unclear. The objective of the current study was to elucidate the effectiveness of adjuvant chemotherapy in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, pT1b-c/N0-1/M0 ILC. Methods: Based on Surveillance, Epidemiology, and End-Results (SEER) database, we identified original 12334 HR-positive, HER2-negative, pT1b-c/N0-1/M0 ILC patients, who were then divided into adjuvant chemotherapy group and control group. End-points were overall survival (OS) and breast cancer-specific mortality (BCSM). Aiming to minimize the selection bias of baseline characteristics, Propensity Score Matching (PSM) method was used. Results : In a total of 12334 patients with HR-positive, HER2-negative, pT1b-c/N0-1/M0 ILC, 1785 patients (14.5%) were allocated into adjuvant chemotherapy group and 10549 (85.5%) into control group. Used PSM, the 1785 patients in adjuvant chemotherapy group matched to the 1785 patients in control group. By Kaplan-Meier survival analyses, we observed no beneficial effect of adjuvant chemotherapy on OS in both original samples ( P =0.639) and matched samples ( P =0.962), however, ineffective or even contrary results of adjuvant chemotherapy on BCSM both in original samples (P =0.001) and in matched samples ( P= 0.002). In both original and matched multivariate Cox models, we observed ineffectiveness of adjuvant chemotherapy on OS (hazard ratio (HR) for overall survival = 0.82, 95% confidence interval (CI) [0.62-1.09]; P =0.172 and HR=0.90, 95%CI [0.65-1.26]; P =0.553, respectively), unexpectedly promoting effect of adjuvant chemotherapy on BCSM (HR=2.33, 95%CI [1.47-3.67]; P =0.001 and HR=2.41, 95%CI [1.32-4.39]; P =0.004, respectively). Standard surgery was beneficial to the survival of patients. Lymph node metastasis was detrimental to survival and radiotherapy brought survival benefit in original samples, but two issues had unobvious effect in matched samples. Conclusion: In this study, adjuvant chemotherapy did not improve survival for patients with HR-positive, HER2-negative pT1b-c/N0-1/M0 ILC.

show abstract

A new WHO classification of prostate tumors

Cited by 13 publications

References 2 publications

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

Prostate pathological evaluation after radical prostatectomy

Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

Contact Info

Product

Resources

About